Skip Navigation

Nephrology Dialysis Transplantation 2007 22(Supplement 4):iv1; doi:10.1093/ndt/gfm159
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carrera, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Carrera, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. for Permissions, please email: journals.permissions@oxfordjournals.org

Foreword

The first 10% of the full text of this article appears below.

While important advances in the management of anaemia associated with chronic kidney disease (CKD) have been made over the past 20 years, the need to optimize anaemia management continues. Erythropoiesis-stimulating agents (ESAs) have been the best tool in anaemia management since the first ESA, recombinant human erythropoietin (epoetin alfa), was introduced nearly two decades ago. The newer ESA, darbepoetin alfa, allows the move from standard twice- or thrice-weekly administration to extended dosing regimens . . . [Full Text of this Article]

Fernando Carrera

Guest Editor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?